Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847559 | 0.87 | CYP2A6 (0.54) | METAP1SRD5A1PARP10PARP11PARP1 | |
| SCHEMBL1701852 | 0.87 | CYP2A6 (0.54) | METAP1SRD5A1PARP10PARP11PARP1 | |
| SCHEMBL6905898 | 0.78 | ALDH1A1 (0.47) | METAP1SRD5A1PARP10PARP11PARP1 | |
| SCHEMBL597333 | 0.78 | DPP4 (0.49) | METAP1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL414198 | 0.78 | NPC1 (0.52) | METAP1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL15957847 | 0.77 | PARP10 (0.57) | METAP1SRD5A1PARP10PARP11PARP1 | |
| SCHEMBL20901342 | 0.77 | SRD5A1 (0.49) | METAP1SRD5A1PARP10PARP11PARP1 | |
| SCHEMBL22005789 | 0.76 | DPP4 (0.47) | METAP1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL6902791 | 0.76 | DRD1 (0.49) | ALDH1A1CYP2A6RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL12430501 | 0.75 | METAP1 (0.44) | METAP1PARP10PARP11PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9353124-B2 | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9173882-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9156820-B2 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-08-06 | — | — | US | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2114955-B1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8349838-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | METAP1 1754/4885SRD5A1 4422/4885PARP10 1689/4885 |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | METAP1 1754/4885SRD5A1 4422/4885PARP10 1689/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885SRD5A1 3927/4885PARP10 2609/4885 |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | AXL, BTK, MERTK | METAP1 1946/4885SRD5A1 4432/4885PARP10 2116/4885 |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | METAP1 1754/4885SRD5A1 4422/4885PARP10 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.